WebDoctor Encyclopedia

Head & neck

Carcinoma ex pleomorphic adenoma

Carcinoma ex pleomorphic adenoma is a salivary gland cancer that develops inside a long-standing benign mixed tumour, usually in the parotid. Sudden growth of an old lump is the classic warning sign, and treatment is surgery, often with radiotherapy.

Medically reviewed Last reviewed October 27, 2026

What is carcinoma ex pleomorphic adenoma?

Carcinoma ex pleomorphic adenoma (CXPA) is a salivary gland cancer that develops inside a benign tumour called a pleomorphic adenoma. “Ex” simply means “arising from”. The benign tumour is usually present for years, sometimes decades, before part of it turns malignant.

Pleomorphic adenoma is the most common salivary gland tumour and is almost always harmless when removed completely. Only a small proportion ever becomes cancerous. The risk rises the longer an adenoma is left in place and is higher after repeated recurrences of an adenoma that was not fully removed.

CXPA makes up roughly one in ten salivary gland cancers. Most cases arise in the parotid gland, in front of the ear, and affect people in their 50s and 60s. A typical story is a lump that has been present for many years and then starts to grow quickly.

The outlook depends strongly on how far the cancer has broken out of the old adenoma and on the type of cancer that has formed inside it. Tumours that stay within the adenoma’s capsule behave almost like benign tumours, while widely invasive ones can be aggressive (Antony et al., 2012).

1. Key facts at a glance

Feature Details
Type of cancer Malignant salivary gland tumour arising in a pleomorphic adenoma
How common About 3-4% of all salivary tumours; around 1 in 10 salivary cancers
Typical age Adults, mostly 50-70; usually about 10 years older than people with benign adenomas
Sex Men and women affected about equally
Main site Parotid gland (around 8 in 10); also submandibular and minor salivary glands
Warning sign Sudden growth, pain or facial weakness in a long-standing lump
Main treatment Surgery, often followed by radiotherapy
Outlook Varies widely; about 6 in 10 alive at 5 years overall

2. Types of carcinoma ex pleomorphic adenoma

Pathologists describe CXPA in two ways: how far the cancer has spread beyond the adenoma, and which kind of cancer has developed.

By extent of invasion

Category What it means Usual behaviour
Intracapsular (non-invasive) Cancer cells are still entirely inside the adenoma Excellent; very similar to a benign adenoma
Minimally invasive Cancer has broken through the capsule by only a few millimetres (commonly 4 mm or less) Usually very good
Widely invasive Cancer has spread well beyond the capsule into surrounding tissue Higher risk of recurrence and spread

By the type of cancer inside

Carcinoma type Notes
Salivary duct carcinoma The most frequent; high grade and aggressive
Adenocarcinoma, not otherwise specified Common; behaviour depends on grade
Myoepithelial carcinoma Arises from the outer muscle-like cells of glands
Epithelial-myoepithelial carcinoma Usually lower grade
Others Mucoepidermoid, adenoid cystic and other rarer types

Many tumours are also given a grade. Low-grade carcinomas grow slowly, while high-grade ones such as salivary duct carcinoma tend to spread to lymph nodes.

3. Causes and risk factors

CXPA develops from a pre-existing pleomorphic adenoma. Over time, extra genetic damage builds up in some adenoma cells until they become malignant.

Risk factor Notes
Long-standing adenoma The risk grows with the number of years an adenoma has been present
Recurrent adenoma Adenomas that have come back after incomplete removal carry a higher risk
Older age Most people are in their 50s or older
Large adenoma Bigger tumours are more likely to contain cancer
Previous radiation Linked with salivary gland tumours in general

Gene changes

Gene change Notes
PLAG1 or HMGA2 rearrangement Present in the original adenoma; often still found in the carcinoma
TP53 changes Common in high-grade forms
HER2 (ERBB2) amplification Seen in a sizeable share, especially salivary duct type; a treatment target
Androgen receptor (AR) Often present in salivary duct type; a possible treatment target
Other changes PIK3CA, HRAS and others in some tumours (Key et al., 2024)

These changes arise only in the tumour. CXPA is not inherited.

4. How does it look

On the outside

Feature Description
Position Usually in front of or below the ear (parotid); sometimes under the jaw or inside the mouth
Shape A rounded or irregular lump
Feel Firm or hard; may become fixed to the skin or deeper tissues
Size Often 2-6 cm, sometimes much larger after many years
Skin Usually normal; may become red, tethered or ulcerated in advanced cases
Change over time A lump stable for years that suddenly enlarges

On scans

Ultrasound is often the first test for a lump near the ear. MRI is the best scan for showing the tumour’s edges, any spread into nearby tissue and growth along the facial nerve. Irregular, poorly defined margins and areas of tissue death suggest cancer rather than a simple adenoma. CT of the neck and chest, or a PET-CT, checks lymph nodes and the lungs.

Under the microscope

Feature Description
Two components Remnants of the benign adenoma next to clearly malignant tissue
Old adenoma Often scarred, glassy (hyalinised) or calcified
Carcinoma Atypical cells, many cell divisions and areas of necrosis
Invasion Measured in millimetres beyond the capsule
Special stains HER2, androgen receptor and PLAG1 or HMGA2 help with diagnosis and treatment choice

In some tumours the benign component has almost disappeared, so the diagnosis may rest on the history of a long-standing lump or on finding PLAG1 or HMGA2 changes in the cancer.

5. Symptoms

Common symptoms

  • A lump in front of or below the ear, or under the jaw
  • A lump that has been there for years and has recently started growing faster
  • Pain or discomfort in the lump
  • A lump that feels harder or more fixed than before

Less common symptoms

Symptom What it may mean
Weakness of one side of the face Facial nerve involvement; an important warning sign
Numbness Nerve involvement
Lump in the neck Lymph node spread
Skin ulceration Advanced local growth
Swelling in the mouth or throat Minor salivary gland tumour
Cough or breathlessness Rarely, spread to the lungs

When to seek medical advice

Any lump near the ear or under the jaw that persists for more than a few weeks should be checked. If you know you have a pleomorphic adenoma that was not removed, see your doctor promptly if it grows, becomes painful or if your face becomes weak.

6. Diagnosis

Test Purpose
Examination of the head and neck Assesses the lump, facial nerve function and lymph nodes
Ultrasound First look at the lump and the neck nodes
Fine-needle aspiration or core biopsy Takes cells or a thin core of tissue; may miss small areas of cancer
MRI Shows extent, edges and nerve involvement
CT or PET-CT Checks the neck, chest and rest of the body for spread
Final pathology after surgery Confirms the diagnosis, invasion distance, carcinoma type and margins

Needle tests can be misleading, because a small cancer may hide inside a large benign tumour. The diagnosis is therefore often only confirmed after the whole tumour is removed (Antony et al., 2012).

Staging

CXPA is staged in the same way as other major salivary gland cancers, using the TNM system.

Part What it describes
T (tumour) Size, and spread beyond the gland into skin, bone, nerves or other structures
N (nodes) Number, size and side of neck lymph nodes containing cancer
M (metastasis) Spread to distant organs such as the lungs or bones

7. Treatment

Treatment is planned by a head and neck cancer team, which usually includes surgeons, clinical oncologists, pathologists and radiologists.

Surgery

Operation Notes
Parotidectomy Removes part or all of the parotid gland with the tumour
Facial nerve preservation The nerve is kept when it is not involved by cancer
Facial nerve resection and repair If the nerve runs through the tumour; a graft may restore some movement
Submandibular gland excision For tumours under the jaw
Neck dissection Removes lymph nodes when they are involved, and often for high-grade or large tumours
Wide local excision For tumours of the minor salivary glands in the mouth or throat

For intracapsular and minimally invasive tumours removed with clear margins, surgery alone may be enough.

Radiotherapy

Radiotherapy after surgery is commonly advised for widely invasive, high-grade, node-positive or incompletely removed tumours. In a recent two-centre series, about three-quarters of patients received radiotherapy after surgery (Kassalow et al., 2025).

Drug treatment

Option When it may be used
HER2-targeted drugs For HER2-positive tumours that have spread or come back
Androgen deprivation therapy For androgen receptor-positive tumours
Chemotherapy Sometimes with radiotherapy, or for advanced disease
Clinical trials Testing targeted drugs and immunotherapy

Testing the tumour for HER2 and androgen receptor is useful because these results can open up targeted treatment options.

Side effects

Treatment Possible side effects
Parotid surgery Temporary or permanent facial weakness; numbness of the ear lobe; a dent in front of the ear
Frey syndrome Sweating or flushing of the cheek when eating
Neck dissection Shoulder stiffness, neck numbness, swelling
Radiotherapy Skin soreness, dry mouth, taste changes, hearing changes, jaw stiffness

What treatment involves day to day

Stage What to expect
Surgery Usually 1-3 nights in hospital, with a drain for a day or two
Recovery Most people return to normal activities within 2-4 weeks
Radiotherapy Weekday treatments for around 6 weeks, starting 4-8 weeks after surgery
Facial weakness Eye care and facial physiotherapy if needed

8. Outlook (prognosis)

A systematic review of almost 5,600 patients found overall survival of about 72% at 3 years, 62% at 5 years and 45% at 10 years. Higher stage, lymph node spread, high grade and invasion beyond 1.5 mm were linked with poorer survival (Key et al., 2022).

Factor Effect on outlook
Intracapsular or minimally invasive Excellent, close to that of a benign adenoma
Widely invasive Higher risk of recurrence and spread
High grade or salivary duct type Poorer outlook
Lymph node spread One of the strongest predictors of poorer survival (Kassalow et al., 2025)
Clear margins Better local control

Cancer can return in the original area, in the neck or in distant organs such as the lungs and bones. Most recurrences appear within the first 5 years.

9. Follow-up

Follow-up Purpose
Clinic visits every 2-3 months at first Examine the face, scar and neck
Gradually longer intervals Every 6-12 months after the first few years
MRI of the head and neck Looks for local recurrence
CT of the chest Checks the lungs, especially for high-grade tumours
Facial nerve, dental and swallowing review Supports recovery after treatment

10. Living with carcinoma ex pleomorphic adenoma

  • Protect your eye with drops, gel and taping at night if your eyelid does not close fully
  • Do facial exercises taught by a physiotherapist if your face is weak
  • Look after your teeth, especially after radiotherapy, with regular dental check-ups
  • Use saliva substitutes and sip water for a dry mouth
  • Report new lumps, pain or numbness without waiting for your next appointment
  • Seek support from head and neck cancer charities and patient groups

11. Frequently asked questions

Question Answer
Can a benign parotid lump really become cancer? Yes, rarely; this is why pleomorphic adenomas are usually removed
Is it inherited? No
Will I lose movement in my face? Not usually if the nerve is free of tumour, though temporary weakness is common
Do I need radiotherapy? It depends on invasion, grade, margins and lymph nodes
Is chemotherapy usually needed? Not after surgery for most people; it is used mainly for advanced disease
Can it come back? Yes, which is why regular follow-up is important
Why test for HER2? A HER2-positive tumour may respond to targeted drugs

12. Questions to ask your care team

  • How far had the cancer spread beyond the adenoma?
  • What type and grade of carcinoma is it?
  • Were the margins clear, and was the facial nerve involved?
  • Do I need a neck dissection or radiotherapy?
  • Has my tumour been tested for HER2 and androgen receptor?
  • What follow-up scans will I have?

Resources

  1. Antony, J. et al. (2012) ‘Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data’, Head and Neck Pathology, 6(1), pp. 1-9.
  2. Kassalow, B. et al. (2025) ‘Carcinoma ex pleomorphic adenoma: multi-institutional retrospective cohort study’, OTO Open, 9(3), e70147.
  3. Key, S. et al. (2022) ‘Systematic review of prognostic factors in carcinoma ex pleomorphic adenoma’, Oral Oncology, 133, 106052.
  4. Key, S. et al. (2024) ‘Molecular factors in carcinoma ex pleomorphic adenoma: systematic review and meta-analysis’, The Laryngoscope, 134(3), pp. 1042-1053.
  5. National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.